Yong-Sheng Li

机构：Chongqing University, Chongqing Cancer Hospital

发表论文 1 篇 · 总被引 5 次 · h-index 1

代表论文

• Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) (2026 · Nature Communications · 被引 5)